and adjustments to ratings and price targets. Capture valuable insights into HealthEquity's market standing by understanding these analyst evaluations alongside pertinent financial indicators.
HealthEquity (NASDAQ:HQY – Get Free Report) was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a note issued to investors on Tuesday, MarketBeat.com ...
In a report released on March 27, David Roman from Goldman Sachs maintained a Hold rating on Healthequity (HQY – Research Report), with a price ...
Shares of HealthEquity (NASDAQ:HQY) fell ~20% on Wednesday, marking its biggest one-day decline in more than three years, after the health savings account (HSA) administrator failed to meet Street ...
Stocktwits on MSN13d
HealthEquity Stock Sees Biggest Drop In Over 3 Years On Disappointing Outlook — Retail Doesn't Feel It's All Doom And GloomShares of HealthEquity, Inc. fell more than 17% on Wednesday, registering the worst drop since December 2021, after the ...
HealthEquity (NASDAQ:HQY – Free Report) had its price objective trimmed by The Goldman Sachs Group from $107.00 to $94.00 in a report published on Thursday morning,Benzinga reports. The firm currently ...
On a per-share basis, that figure was $0.69. This meant a mixed quarter for HealthEquity. While it beat the average analyst estimate of $305.8 million for revenue, it fell short of the consensus $ ...
HealthEquity stock drops after mixed Q4 results despite 18.8% revenue growth. Click here to find out why HQY stock is a Hold.
HealthEquity, Inc. (NASDAQ:HQY) reported fourth-quarter adjusted EPS of 69 cents, up from 63 cents a year ago, missing the ...
Understanding Analyst Ratings: A Comprehensive Breakdown The standing of HealthEquity among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below ...
Raymond James analyst Gregory Peters upgraded Healthequity (HQY – Research Report) to a Buy yesterday and set a price target of $115.00. The ...
Barrington Research maintains HealthEquity with an Outperform and a $112 price target. Analyst Alexander Paris writes the earnings were impacted by excess costs associated with cyber-fraud ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback